Breaking News

PathAI, GSK Partner on Phase II NASH Clinical Trial

PathAI will provide kitting, logistics, lab and analytical services to generate and analyze digitized H&E and Masson's Trichome data.

PathAI, a provider of AI-powered pathology, entered into a partnership with GSK, on HORIZON, a randomized Phase 2b non-alcoholic steatohepatitis (NASH) clinical trial. The trial is designed to measure improvements in liver histology with GSK4532990 compared with placebo in participants with NASH and advanced fibrosis. PathAI’s role will be to generate, digitize, and analyze liver biopsy slides for central pathologist evaluation in addition to AI-powered histologic evaluation using PathA...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters